MedTrace Logo

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

NCT06604767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2026-04-23

No results posted yet for this study

Summary

The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.

Conditions

  • Respiratory Syncytial Virus Infection
  • Metapneumovirus Infection
  • Parainfluenzae Virus Infection

Interventions

BIOLOGICAL

parainfluenza virus type 3 vaccine (PIV3)

Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular

BIOLOGICAL

RSV/hMPV/PIV3 vaccine

Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

BIOLOGICAL

RSV/hMPV vaccine

Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

BIOLOGICAL

RSV vaccine 1

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

BIOLOGICAL

RSV vaccine 2

Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-17
Primary Completion
2026-03-24
Completion
2026-03-24

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06604767 on ClinicalTrials.gov